Histiocytosis Clinical Trials in Washington D.C., District of Columbia
6 recruitingWashington D.C., District of Columbia
Showing 1–6 of 6 trials
Recruiting
Phase 2
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Recurrent Langerhans Cell HistiocytosisRefractory Langerhans Cell Histiocytosis
National Cancer Institute (NCI)48 enrolled117 locationsNCT05828069
Recruiting
Phase 2Phase 3
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Electra Therapeutics Inc.156 enrolled41 locationsNCT05416307
Recruiting
Project: Every Child for Younger Patients With Cancer
Malignant Solid NeoplasmNeuroendocrine NeoplasmCentral Nervous System Neoplasm+15 more
Children's Oncology Group75,000 enrolled278 locationsNCT02402244
Recruiting
Phase 1Phase 2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Colorectal, CancerColorectal CarcinomaNon-small Cell Lung Cancer+29 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting
Phase 2
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Langerhan's Cell HistiocytosisJuvenile XanthogranulomaErdheim-Chester Disease+4 more
Carl Allen90 enrolled12 locationsNCT04079179
Recruiting
Phase 2Phase 3
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Langerhans Cell Histiocytosis
North American Consortium for Histiocytosis1,400 enrolled42 locationsNCT02205762